The same firm that was alleged to have conducted controversial research at a laboratory in Wuhan, China—the city where COVID-19 emerged in 2019—has received a new grant to study bat viruses.
The study will involve bats and coronaviruses and is set to run until Aug. 31, 2027. However, its research won’t take place in China but instead will focus on Laos, Vietnam, and Burma (also known as Myanmar).
“Our hotspots risk mapping suggests countries directly to the south of China; Myanmar, Laos, and Vietnam in particular; contain regions with human-wildlife interfaces 8 and likely regular spillover of novel [coronaviruses] from bats and other wildlife,” it said.
The grant was awarded by the National Institutes of Health (NIH) on Sept. 21, with the total project funding for the year 2022 being $653,392.
EcoHealth added that its “preliminary field studies have identified novel viruses related to known zoonoses in bats and other wildlife from each of these countries” with an overall goal to “analyze the behavioral and environmental risk factors for spillover of” new coronavirus strains and identify any “wildlife-to-human spillover events.”
Criticism
“It should be noted that EcoHealth Alliance was awarded a new NIH grant ten days ago, providing an additional $3.3 M over five years for a project including high-risk virus discovery research in bats in Southeast Asia,” Rutgers University professor of chemical biology Richard Ebright wrote on Twitter about the latest NIAID grant on Sept. 30.Days after the grant was handed out, Sen. Joni Ernst (R-Iowa) introduced legislation that would ban providing federal funds to EcoHealth Alliance, specifically over its research at the Wuhan lab.
In an interview with Science.org last year, EcoHealth chief Peter Daszak said that he is the victim of “an antiscience attack” and claimed that he was warning about a coronavirus pandemic for 15 years before COVID-19 spread across the world.
The NIH and EcoHealth Alliance didn’t respond by press time to a request by The Epoch Times for comment.